A Double-Blind, Placebo-Controlled (Sham Surgery), Randomized, Multicenter Study Evaluating CERE-110 Gene Delivery in Subjects With Mild to Moderate Alzheimer's Disease

Trial Profile

A Double-Blind, Placebo-Controlled (Sham Surgery), Randomized, Multicenter Study Evaluating CERE-110 Gene Delivery in Subjects With Mild to Moderate Alzheimer's Disease

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Jan 2017

At a glance

  • Drugs CERE 110 (Primary)
  • Indications Alzheimer's disease
  • Focus Therapeutic Use
  • Sponsors Ceregene
  • Most Recent Events

    • 22 Apr 2015 According to a company media release, Sangamo BioSciences has terminated the CERE-110 program.
    • 22 Apr 2015 Status changed from active, no longer recruiting to completed according to a Sangamo BioSciences media release.
    • 26 Aug 2013 Results are now expected in 2015 according to a Sangamo Biosciences, who acquired Ceregene, as announced in a company media release. Patients are presently in the follow-up stage.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top